NVNO

enVVeno Medical Corp

NVNO, USA

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

https://www.envveno.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NVNO
stock
NVNO

enVVeno Medical Holds Annual Stockholders Meeting TipRanks

Read more →
NVNO
stock
NVNO

EnVVeno Medical shareholders approve reverse stock split, reject equity plan By Investing.com Investing.com UK

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$12.5

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.22

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-15.41 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-14.03 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.10

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 32.98% of the total shares of enVVeno Medical Corp

1.

Perceptive Advisors LLC

(6.6761%)

since

2025/06/30

2.

Kingdon Capital Management LLC

(4.4644%)

since

2025/06/30

3.

Vanguard Group Inc

(3.6283%)

since

2025/06/30

4.

Nantahala Capital Management, LLC

(3.0896%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(2.4188%)

since

2025/07/31

6.

Westside Investment Management, Inc.

(1.4523%)

since

2025/06/30

7.

UBS O'Connor LLC

(1.253%)

since

2025/06/30

8.

Vanguard Institutional Extnd Mkt Idx Tr

(1.1692%)

since

2025/07/31

10.

AvH Emerging Markets Fonds UI A

(1.0391%)

since

2025/06/30

11.

Geode Capital Management, LLC

(1.0366%)

since

2025/06/30

12.

JPMorgan Chase & Co

(0.9472%)

since

2025/06/30

13.

Altium Capital Management, LP

(0.6404%)

since

2025/03/31

14.

Fidelity Extended Market Index

(0.4892%)

since

2025/07/31

15.

Morgan Stanley - Brokerage Accounts

(0.3914%)

since

2025/06/30

16.

Regions Financial Corp

(0.3559%)

since

2025/06/30

17.

Northern Trust Corp

(0.3149%)

since

2025/06/30

18.

BlackRock Inc

(0.2982%)

since

2025/06/30

19.

State Street Corp

(0.212%)

since

2025/06/30

20.

Fermata Advisors, LLC

(0.2081%)

since

2025/06/30

21.

iShares Micro-Cap ETF

(0.2026%)

since

2025/08/31

22.

Fidelity Total Market Index

(0.154%)

since

2025/07/31

23.

Citadel Advisors Llc

(0.1512%)

since

2025/06/30

24.

Laird Norton Tyee Trust Co

(0.1299%)

since

2025/06/30

25.

Fidelity Series Total Market Index

(0.128%)

since

2025/07/31

26.

Spartan Extended Market Index Pool F

(0.1087%)

since

2025/07/31

27.

Fidelity Nasdaq Composite Index

(0.1064%)

since

2025/07/31

28.

HOHIMER WEALTH MANAGEMENT, LLC

(0.1039%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - L

(0.1035%)

since

2025/06/30

30.

Northern Trust Extended Eq Market Idx

(0.1035%)

since

2025/06/30

31.

XTX Topco Ltd

(0.0916%)

since

2025/06/30

32.

NT Ext Equity Mkt Idx Fd - NL

(0.0907%)

since

2025/06/30

33.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0704%)

since

2025/06/30

34.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0608%)

since

2024/12/31

35.

Vanguard Instl Ttl Stk Mkt Idx InstlPls

(0.0608%)

since

2025/07/31

36.

Extended Equity Market Fund K

(0.0602%)

since

2025/06/30

37.

Spartan Total Market Index Pool G

(0.0559%)

since

2025/07/31

38.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0292%)

since

2025/06/30

39.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0247%)

since

2024/12/31

40.

1290 VT Micro Cap K

(0.0187%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.2252

EPS Estimate

-0.3

EPS Difference

0.0748

Surprise Percent

24.9333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Strong Net-Net(6.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.